CLINICAL EVIDENCE OVERVIEW

In a 2001 study of 30 healthy adult men with a mean age of 36.2 years, participants received 300 mg of the PurpleForce® bone supplement in a prepared beverage over 16 days⁽¹⁾. The results showed that PurpleForce® promoted bone formation and suppressed bone resorption, while maintaining the balance of bone remodeling.

In a 2001 study⁽²⁾, 33 healthy women (with a mean age of 28.8 years) received 40 mg of PurpleForce® per day over six months. Researchers found that PurpleForce® supplementation increased participants bone mineral density (BMD). “Daily PurpleForce® supplementation of 40 mg in healthy adult women can significantly increase their BMD [bone mineral density] independent of their dietary intake of minerals and vitamins; this increase in BMD might be primarily mediated through inhibition of osteoclast-mediated bone resorption by PurpleForce® supplementation.”

A subsequent report published in a 2002 issue of Bioscience, Biotechnology & Biochemistry⁽³⁾ explained, “It appears that 40 mg per day of PurpleForce® supplementation is effective in promoting bone metabolism and an increase in BMD, at least in their radius. PurpleForce® can thus be considered [a bone health supplement] capable of increasing peak bone mass and reducing further risk of osteoporosis in premenopausal women.”

In 2005, researchers gave 40 mg of the PurpleForce® bone supplement or a placebo to 32 healthy menopausal women (with a mean age of 50.5 years) for six months⁽⁴⁾. They concluded: “These results suggested that PurpleForce® supplementation was effective in preventing bone loss in menopausal women and that this improvement in BMD may be primarily mediated through the inhibition of bone resorption while maintaining the balance of bone remodeling by PurpleForce® supplementation.”

Researchers, in 2007, administered 40 mg of PurpleForce® or a placebo to 35 healthy adult women (with a mean age of 21.3 years) each day for six months⁽⁵⁾. The authors found: “These results suggested that PurpleForce® supplementation was effective in increasing BMD in young women and that this increase in BMD may be primarily mediated through the promotion of bone formation and inhibition of bone resorption by PurpleForce® supplementation.

Scientists, in 2010, gave 40 mg of PurpleForce® to elderly women (with a mean age of 65 to 86 years) for 12 months⁽⁶⁾. The findings? “PurpleForce® reduced markers of bone loss, particularly in the lower extremities. Reduced resorption of bone was also associated with moderate-intensity/duration exercise, PurpleForce® therapy interacting significantly with habitual physical activity.”